Anupam Rasayan India: Q3 & 9M FY26 Performance and Strategic Expansion

Anupam Rasayan India Ltd., a prominent player in the specialty chemical sector, has reported a robust financial performance for the third quarter and nine months ended December 31, 2025 (9M FY26). The company's consolidated revenue for 9M FY26 surged by an impressive 84% year-on-year to ₹1,730 crore, reflecting strong operational momentum. This growth was complemented by a 53% increase in EBITDA, reaching ₹402 crore, and a significant 71% rise in Profit After Tax (PAT) to ₹166 crore. For the standalone Q3 FY26, revenue stood at ₹512.4 crore, marking a 31% year-on-year growth, with EBITDA at ₹129.6 crore and PAT at ₹60.6 crore.

The company's diversified revenue streams played a crucial role in this performance. For 9M FY26, the Agro segment contributed 56% of the total revenue, followed by Pharma at 19%, Performance Materials at 17%, and Personal Care at 9%. The Agro segment, in particular, showed a healthy revival in demand, supported by improving channel inventory levels and a gradual normalization of global demand. The Pharma segment continued its trajectory as a key growth driver, with a strategic focus on import substitution of critical starting materials and intermediates for high-value pharma products. Performance Materials, encompassing defense and electronic materials, also delivered strong growth, contributing significantly to the overall revenue.

Strategic Expansion and Global Footprint

A significant highlight of the period is Anupam Rasayan's strategic expansion into the United States through the definitive agreement to acquire 100% equity in Jayhawk Fine Chemicals LLC. This U.S.-based specialty chemicals company, with an enterprise value of approximately $134 million, is set to significantly enhance Anupam Rasayan's global footprint and capabilities in advanced custom synthesis. The acquisition, which is expected to be EPS accretive from day one, will provide direct onshore manufacturing presence in the US, deepening access to regulated markets and innovator customers in North America. This move aligns with the company's long-term objective of evolving into a global specialty chemical platform, serving high-growth and high-value sectors such as semiconductors, automotive, EV, pharma, aviation, and electronics.

Further details from corporate announcements reveal the intricate structure of this acquisition. Anupam Rasayan's board approved the acquisition of Doriath S.à r.l., a wholly-owned subsidiary in Luxembourg, which is intended to be the affiliate that will acquire Jayhawk. The acquisition of Doriath was completed on February 10, 2026. Additionally, the company approved the acquisition of a 15% equity stake in Batam S.à r.l., another Luxembourg entity. These Luxembourg entities are primarily established to create a corporate presence in the region and provide consultancy services, with the company intending to assist Batam in its business activities. The financing for these acquisitions involves credit facilities, including USD 20 million for Doriath and a USD 30 million External Commercial Borrowing (ECB) facility for Anupam Rasayan, along with various security arrangements.

Backward Integration and R&D Prowess

Anupam Rasayan's strategic foresight is also evident in its backward integration efforts. The acquisition of a ~26% stake in Tanfac Industries Ltd. in May 2022 has proven instrumental in securing uninterrupted access to key raw materials like Hydrofluoric Acid (HF) and Potassium Fluoride (KF), which are critical for fluorination chemistry. This integration reduces supply chain risk, improves cost stability, and enhances reliability for global customers, while also enabling the development of high-value-added fluorine intermediates. The company is actively leveraging this fluoro platform to manufacture Value Added Products (VAPs), targeting a revenue potential of $220 -$260 million from an addressable market of $5+ billion in polymers, pharmaceuticals, and agrochemicals.

Innovation remains at the core of Anupam Rasayan's strategy, supported by its DSIR recognized R&D center. With a team of over 90 R&D professionals and a capital expenditure of ₹55 crore in R&D over the last five years, the company is at the forefront of deploying new technologies like Flow Chemistry and Photo Chemistry. These advancements aim to reduce lead times, enhance material efficiency, lower costs, and simplify the synthesis of complex molecules, thereby expanding access to novel compounds.

Market Opportunities and Future Outlook

Anupam Rasayan is strategically positioned to capitalize on significant market opportunities. In Pharmaceuticals, the company is targeting a Total Addressable Market (TAM) of ~$15 billion, with an expected CAGR growth of ~5$10 billion, with a projected CAGR growth of ~4% over the same period. The company's focus on high-value intermediates across applications like defense, aerospace, electronics, ionomers, and semiconductors underscores its commitment to diversifying into less cyclical, high-margin segments.

Despite the strong growth, the company observed a decline in consolidated Gross Margins from 61% in 9M FY25 to 43% in 9M FY26, and EBITDA Margins from 28% to 23% in the same period. Management is actively addressing operational efficiencies, including a target to reduce working capital intensity from approximately 250 days to around 180 days or below by FY27. The strong order book of ₹14,646 crore as of Q4 FY25 provides significant revenue visibility and confidence in sustaining the growth trajectory.

Anupam Rasayan India's Q3 and 9M FY26 performance demonstrates a clear strategic direction focused on diversified growth, global expansion, and technological leadership. The Jayhawk acquisition and continued emphasis on fluorination chemistry, coupled with robust R&D, position the company for sustained long-term value creation in high-value specialty chemical markets. The management's confident outlook, backed by a strong pipeline and strategic initiatives, reinforces its commitment to disciplined execution and shareholder trust.